🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Just out on NEJM FLAURA2⃣ Phase 3⃣ trial, first-line treatment with osimertinib in combination with chemotherapy 🧪significantly extended progression-free survival in 🧬EGFR-mutated advanced non-small-cell lung cancer 🫁patients compared to osimertinib monotherapy, with higher

Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC: the abstract of the #ESMOVirtualPlenary presented on November 16th 2023 is available in Annals of Oncology annalsofoncology.org/article/S0923-… ESMO - Eur. Oncology Hochmair Maximilian Curioni_Oncology_MD #LCSM

Cancer of unknown primary CUP Perfect for precision oncology Impact of knowing unknown through multi-omics Rate of SD>=6 months/PR/CR = 71% versus 24% (p= 0.003) for well matched versus poorly molecularly matched patients 🎯🔥hit the target

The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors dlvr.it/SyzDCL

JUST IN: U.S. FDA approved belzutifan (HIF2 inhibitor) in advanced renal cell carcinoma (RCC) following PD1 and VEGF inhibitors! A great day for the field and a new option for our Kidney Cancer patients!!!! Via ASCO #FDAAlerts OncoAlert Study presented at ESMO - Eur. Oncology #ESMO3 by

A Systematic Approach to Optimize the Implementation of #Precision #Oncology in Clinical Practice: A Meeting Proceeding meridian.allenpress.com/innovationsjou…

#Cancer treatment selection using #AI #immunotherapy #precision #ArtificialIntelligence nature.com/articles/d4158…

You'll see at #ASCO24 that the ASCO team continues to build upon its evidence-based focus on how people learn. We've asked speakers to lead with their conclusions, because we all remember what we hear first and last, and what we hear multiple times. We're also better able to

Changes in ASCO presentations

10x Your Productivity

#cancer #oncology

Just out on The Lancet Oncology The Phase3 SENOMAC🇸🇪Trial in #BreastCancer Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial In

This is such an elegant paper about renal cell cancer tumor metabolism in nature : TCA cycle is suppressed in primary ccRCC but ENHANCED in metastatic ccRCC: work in humans and mice! Much respect @RJDLab and Team UT Southwestern Medical Center

Recent brief report by Limaye et al. explores "Novel Effective Therapeutic Regimen for Recurrent/Metastatic Head and Neck Squamous Cell Cancer" doi.org/10.36401/JIPO-… #immunotherapy #chemotherapy Shambhavi Singh Sewanti Limaye 🇮🇳🇺🇸 Innovations Journals Innovative Oncology Network

#CallforAbstracts: The #IPOF2025 Scientific Committee is seeking studies of artificial intelligence use in precision medicine. Submit an abstract at loom.ly/NMj-9GU Innovative Oncology Network Innovations Journals Innovative Healthcare Institute #oncology #IPOF #AI #artificialintelligence

Review the current treatment options for Granulosa cell tumor #GCT including the role of novel therapies and immune checkpoint inhibitors doi.org/10.36401/JIPO-… by Salkeni et al. #JIPO #granulosacelltumors #rarecancers #FOXL2 Innovative Oncology Network

November marks #NationalStomachCancerAwarenessMonth. Let’s work together to enhance awareness & improve outcomes for those affected by stomach cancer. Innovative Oncology Network loom.ly/mXNa1WI

Sheshadri et al. discuss the incidence, timing of onset, & imaging patterns of pneumonitis, specifically in relation to newly approved precision oncologic agents doi.org/10.36401/JIPO-… #JIPO #pneumonitis #precisiononcology Ajay Sheshadri S Faiz @mehmetaltanmd Innovative Oncology Network

Learn the importance of multidisciplinary workup and management of respiratory symptoms and insufficiency in this case study about a patient w renal cell carcinoma by Faiz et al. Ajay Sheshadri doi.org/10.36401/JIPO-… #immunotherapy #ICIs #JIPO Innovative Oncology Network

Review recent #JIPO case study by Fox et al. "Durable remission after targeted therapy in BRAF V600E-mutant metastatic colorectal cancer" doi.org/10.36401/JIPO-… #vemurafenib #colorectalcancer #dMMR Innovative Oncology Network